Opinion

Video

Key Takeaways on the Evolving NMIBC Treatment Landscape

Author(s):

Gordon A. Brown, DO,Siamak Daneshmand, MD

The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.

Current Time 0:00
Duration 4:55
Loaded: 3.33%
Stream Type LIVE
Remaining Time 4:55
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
    How recombinant BCG could ease strain of supply issues
    Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
    Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
    John Taylor, III, MD, on novel options in NMIBC
    John Taylor, III, MD, on novel options in NMIBC
    Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
    Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
    3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    What a long-term study of patients undergoing RARC reveals about upstaging
    Sima Porten, MD, on the increased risk of bladder cancer among firefighters
    Sima Porten, MD, on the increased risk of bladder cancer among firefighters
    Jason Hafron, MD, predicts coming advancements in bladder cancer
    Jason Hafron, MD, predicts coming advancements in bladder cancer
    Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
    Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
    Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
    Chad Reichard, MD, on the Expanded Access Program for recombinant BCG
    Neeraja Tillu, MD, answers a question during a Zoom video interview
    Neeraja Tillu, MD, discusses predictors of upstaging following RARC for NMIBC
    Related Content
    Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan
    March 31st 2025

    Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

    Michigan Institute of Urology
    Michigan Institute of Urology is a clinical trial site for LEGION-100.
    medical depiction of bladder cancer
    May 31st 2023

    Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

    Urology Times staff
    In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
    FDA approves durvalumab/chemo for muscle–invasive bladder cancer
    March 28th 2025

    FDA approves durvalumab/chemo for muscle–invasive bladder cancer

    Hannah Clarke
    The approval is supported by results from the phase 3 NIAGARA trial.
    Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
    May 26th 2022

    Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

    Urology Times staff
    “We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.
    Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC
    March 26th 2025

    Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC

    Andrea Necchi, MD Hannah Clarke
    "Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
    Bel-sar shows promising safety, efficacy in NMIBC
    March 26th 2025

    Bel-sar shows promising safety, efficacy in NMIBC

    Hannah Clarke
    In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.
    © 2025 MJH Life Sciences

    All rights reserved.